



**FOR IMMEDIATE RELEASE**

Contact: Joanne Westphal

202-572-7756

jwestphal@phrma.org

**Jay Goodman, PhD, and Janice B. Schwartz, MD  
Receive PhRMA Foundation Award in Excellence**

*Respected research leaders are recognized for outstanding contributions to science*

(April 11, 2019) Noted researchers Jay Goodman, PhD, of Michigan State University and Janice B. Schwartz, MD, of the University of California, San Francisco, have received the PhRMA Foundation's highest honor – its Award of Excellence – recognizing lifetime professional achievements.

The Award in Excellence program honors individuals who received PhRMA Foundation grant support at the outset of their careers in a discipline important to the research-based pharmaceutical industry and went on to distinguish themselves through their scientific and/or academic achievements.

“Dr. Goodman and Dr. Schwartz have made contributions to research that ultimately have benefited patients, helping advance our understanding of pharmacology and toxicology tremendously,” said Eileen Cannon, President of the PhRMA Foundation. “Their accomplishments confirm that providing promising young researchers with financial support early in their careers can pay remarkable long-term dividends for the advancement of science.”

**Jay Goodman, PhD – Award of Excellence in Pharmacology/Toxicology**

An author, lecturer and research leader, Dr. Goodman has focused his toxicology research on understanding how chemicals adversely affect human health, particularly in cancer. He has published extensively, including more than 135 studies and contributions to journals and other publications, and has served as an editor and contributor for various leading toxicology journals.

As an international leader in toxicology, Dr. Goodman has served as a member of the International Scientific Program Planning Committee for the International Congress of Toxicology. He is the first American to serve on a EUROTOX committee, which fosters Toxicology, both scientifically and educationally, in all countries of Europe.

He has also been a leader in various professional organizations, including serving the Society of Toxicology as President in 1999-2000. Other leadership positions include serving as a member or in an advisory capacity for the Toxicology Forum; the NIH, CDC and FDA. He is currently a member and former Chair of the International Life Sciences Institute, Health and Environmental Sciences Institute.

Dr. Goodman is the recipient of many awards and honors, including the International Society of Regulatory Toxicology and Pharmacology's International Achievement Award; the Society of Toxicology's Merit Award; the John Barnes Prize Lecture, awarded by the British Toxicology Society; and the George H. Scott Memorial Award, awarded by the Toxicology Forum. He received the Distinguished Alumnus Award from the University of Michigan.

He chaired the Department of Pharmacology and Toxicology's Graduate Committee at Michigan State University (MSU) for 18 years, and during his tenure MSU's toxicology program experienced remarkable growth and maturation. He also served as Interim Chairperson of the department from 2001 to 2002.

Dr. Goodman received the PhRMA Foundation's Research Starter Grant in Pharmacology and Toxicology in 1972. He earned a Ph.D. in pharmacology at the University of Michigan, and has been affiliated with MSU for 48 years.

### **Janice B. Schwartz, MD – Award in Excellence in Clinical Pharmacology**

Janice B. Schwartz, MD, a Professor of Medicine in Geriatrics at the University of California, San Francisco (UCSF), is a board-certified internist and cardiologist with a distinguished record of leadership and research in clinical pharmacology and geriatric medicine.

Her career in academia has included posts at Medicine at Baylor College of Medicine, Northwestern University and at UCSF, where she has led a variety of important research initiatives over the last two decades, focusing on understanding drug responses to medications and especially factors leading to altered drug responses in older patients.

Dr. Schwartz has been an active member of cardiology, clinical pharmacology and geriatric professional societies. She is a past president of the Society for Geriatric Cardiology and past Vice President of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), past member of the Board of Directors and a former member of the ASCPT Editorial Board. She was a recipient of the William B. Abrams Award in Geriatric Clinical Pharmacology from ASCPT.

She has served on National Institutes of Health peer-review committees for more than sixteen years during her career and served on the Advisory Panel on Geriatrics, USP Pharmacopeial Convention, Inc., and on the Institute of Medicine's Committee on Pharmacokinetics and Drug Interactions in the Elderly.

Dr. Schwartz has received continuous funding from the National Institutes of Health since 1985 that has resulted in more than 140 publications in scientific peer-reviewed journals. She has authored 18 book chapters, including one on treatment of the elderly with cardiovascular disease in the premier textbook of cardiology for the past three editions, has served on the Editorial Boards of a number of scientific journals and is currently an Associate Editor of *Trends in Cardiovascular Medicine*. Her writings also reach out to the public to improve patient-centered care through an Expert Advice Health column for the *San Francisco Chronicle*.

Dr. Schwartz received the PhRMA Foundation's Faculty Development Award in Clinical Pharmacology in 1982. She received her medical degree from Tulane University School of Medicine and completed an internal medicine residency training at Cedar Sinai Medical Center, Los Angeles.

### **About the PhRMA Foundation**

For more than 50 years, the PhRMA Foundation has been helping to build a larger pool of highly-trained, top-quality scientists to meet the growing needs of scientific and academic institutions, government, and the research-intensive pharmaceutical industry. To advance this mission, the PhRMA Foundation has awarded more than \$90 million in competitive research fellowships and grants since its founding. The Foundation's emphasis on evidence-based research that determines the true value of medicines is supported by its Value Assessment Initiative. To date, the Foundation has awarded more

than \$2.8 million to support a variety of research projects to help advance this goal, including the establishment of four national Centers of Excellence in Value Assessment.

To learn more, please visit [www.phrmafoundation.org](http://www.phrmafoundation.org)

###